UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 656

Sortiert nach

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

Nephrology, dialysis, transplantation, 2009-05, Vol.24 (5), p.1663-1671

2009

Volltextzugriff (PDF)

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

American journal of kidney diseases, 2014-12, Vol.64 (6), p.821-835

2014

Volltextzugriff (PDF)

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

The American heart journal, 2013-08, Vol.166 (2), p.217-223.e11

2013

Volltextzugriff (PDF)

Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database

American journal of kidney diseases, 2012-01, Vol.59 (1), p.75-83

2012

Volltextzugriff (PDF)

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

The New England journal of medicine, 2017-08, Vol.377 (7), p.644-657

2017

Volltextzugriff (PDF)

Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study

American journal of kidney diseases, 2012-11, Vol.60 (5), p.804-811

2012

Volltextzugriff (PDF)

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics

Kidney & blood pressure research, 2018-01, Vol.43 (1), p.181-190

2018

Volltextzugriff (PDF)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

Therapeutic advances in endocrinology and metabolism, 2021, Vol.12, p.2042018820974191-2042018820974191

2021

Volltextzugriff (PDF)

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?

The New England journal of medicine, 2013-11, Vol.369 (20), p.1960-1962

de Zeeuw, Dick

2013

Volltextzugriff (PDF)

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

Kidney international, 2021-02, Vol.99 (2), p.346-349

2021

Volltextzugriff (PDF)

Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy

Seminars in nephrology, 2007-03, Vol.27 (2), p.172-181

de Zeeuw, Dick, MD, PhD

2007

Volltextzugriff (PDF)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Diabetologia, 2019-10, Vol.62 (10), p.1854-1867

2019

Volltextzugriff (PDF)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Diabetologia, 2019-06, Vol.62 (6), p.926-938

2019

Volltextzugriff (PDF)

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

Journal of the American Society of Nephrology, 2019-11, Vol.30 (11), p.2229-2242

2019

Volltextzugriff (PDF)

Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes

Diabetes care, 2005-10, Vol.28 (10), p.2525-2530

2005

Volltextzugriff (PDF)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.926-935

2017

Volltextzugriff (PDF)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

Diabetes, obesity & metabolism, 2017-03, Vol.19 (3), p.387-393

2017

Volltextzugriff (PDF)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

Diabetes, obesity & metabolism, 2021-02, Vol.23 (2), p.382-390

2021

Volltextzugriff (PDF)

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

American journal of nephrology, 2017-12, Vol.46 (6), p.462-472

2017

Volltextzugriff (PDF)

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes

Kidney international, 2015-01, Vol.87 (1), p.20-30

2015

Volltextzugriff (PDF)

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

Journal of the American Society of Nephrology, 2008-05, Vol.19 (5), p.999-1007

2008

Volltextzugriff (PDF)

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

Journal of the American Society of Nephrology, 2020-05, Vol.31 (5), p.1128-1139

2020

Volltextzugriff (PDF)

Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2368-2383

2019

Volltextzugriff (PDF)

Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2419-2422

2023

Volltextzugriff (PDF)

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

The Lancet (British edition), 2010-11, Vol.376 (9752), p.1543-1551

2010

Volltextzugriff (PDF)

1 – 25 von 656

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(605)
Mit Volltextzugriff
(611)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(473)
Life Sciences & Biomedicine
(460)
Humans
(395)
Male
(274)
Female
(228)
Biological And Medical Sciences
(203)
Urology & Nephrology
(202)
Middle Aged
(198)
Medical Sciences
(191)
Aged
(159)
Risk Factors
(123)
Diabetes
(112)
Adult
(106)
Cardiovascular System & Cardiology
(91)
Animals
(90)
Glomerular Filtration Rate
(84)
Diabetes Mellitus, Type 2 - Complications
(81)
Nephrology. Urinary Tract Diseases
(81)
Blood Pressure
(75)
Albuminuria
(71)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)

Menü

Weitere Dienste

Einstellungen

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality

Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Suchergebnisse filtern